Connect Biopharma Shifts to Direct Listing on Nasdaq for Growth

Author: Kelly Martin Updated: 07-21-2025 09:02 AM

Transforming Investment Accessibility: Connect Biopharma's Move

Connect Biopharma Holdings Limited, known for its commitment to innovative biopharmaceuticals, is taking a significant step forward. The company has announced its plans to discontinue its American Depositary Receipt (ADR) program in favor of a direct listing for its ordinary shares on the Nasdaq Global Market. This transition aims to streamline operations and enhance investor engagement.

What the Changes Mean for Shareholders

Set to take place around September 2, 2025, the termination of the ADR program will involve the mandatory cancellation of existing ADRs, which will be converted into ordinary shares on a one-for-one basis. After this process, Connect Biopharma’s ordinary shares will commence trading on Nasdaq under the symbol “CNTB,” providing an opportunity for broader market visibility.

Enhancements in Investor Engagement

As CEO Barry Quart emphasized, this strategic move is pivotal in evolving Connect Biopharma into a more U.S.-centric organization. By transitioning to a direct listing, the company aims to eliminate depositary fees associated with ADRs, ultimately enriching the shareholder experience. This transition aligns with their goal of expanding their institutional investor base.

Focus on Clinical Advancement

Connect Biopharma is committed to transforming care for individuals suffering from inflammatory diseases, with a keen focus on conditions like asthma and chronic obstructive pulmonary disease (COPD). The company's product candidate, rademikibart, is currently undergoing Phase 2 clinical trials aimed at addressing significant unmet needs in the treatment space.

Groundbreaking Treatment Development

Rademikibart is a novel, potentially best-in-class antibody targeting IL-4R?, which is crucial in the inflammatory response linked to asthma and COPD. The company is not only driving forward with clinical studies globally but is also collaborating with Simcere in China, enhancing their reach and impact in the biopharmaceutical arena.

Keeping Stakeholders Informed

Connect Biopharma plans to proactively notify ADR holders about the program's termination through a formal announcement expected on August 18, 2025. This communication will clarify the upcoming changes and provide necessary details to ensure a smooth transition for all stakeholders.

Conclusion: A Forward-Looking Strategy

The shift toward a direct listing on Nasdaq signifies an important evolution for Connect Biopharma. It represents not only a practical adjustment in its operational framework but also a strategic enhancement in its market presence. With a strong focus on the progress of rademikibart, the company is poised to build long-term shareholder value while striving to deliver expansive treatment options for asthma and COPD patients.

Frequently Asked Questions

What is the reason for terminating the ADR program?

The termination aims to simplify operations, improve investor accessibility, and eliminate related fees.

What will happen to current ADR holders?

Current ADRs will be converted to ordinary shares in a one-for-one ratio after the program termination.

When will the direct listing on Nasdaq occur?

The direct listing is expected to take effect around September 2, 2025.

How will this affect the company’s visibility?

This transition is anticipated to enhance institutional visibility and attract a broader investor base.

What is rademikibart?

Rademikibart is a promising antibody undergoing clinical trials aimed at treating asthma and COPD, focusing on unmet medical needs.

About The Author

Hello Kelly Martin here, a financial and publicly traded company specialist committed to writing with clarity and sage advice. Having a wealth of experience and a thorough grasp of corporate dynamics and the financial environment, my main goal in writing blog posts and articles is to provide insightful analysis together with useful guidance. My objective is to arm readers with the information they need to comprehend the complexities of publicly traded companies and make wise financial decisions.

Writing for several financial blogs has let me interact with a wide range of readers, from novice investors to seasoned pros looking for fresh perspectives. My goal is to make corporate analysis and finance understandable and interesting so you may confidently negotiate the intricacies of the financial world. I appreciate you traveling with me toward success and financial literacy.

Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.